Key Takeaways AstraZeneca posted 8% revenue and 11% core EPS growth in 2025, led by 16 blockbusters.AZN guides mid-to-high single-digit 2026 revenue growth and targets $80B sales by 2030.Pfizer faces COVID declines and a 2026 LOE hit, with sales and EPS seen falling next year.Pfizer (PFE) and AstraZeneca (AZN) are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company revenues. Beyond cancer therapies ...

Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients with hemophilia A or B without inhibitors. HYMPAVZI currently hold ...

Core Insights - Pfizer's total revenue for 2025 was $62.6 billion, a 2% year-over-year decline, but core business revenue grew by 6% when excluding COVID-19 products, indicating robust growth in non-COVID segments [1] - Adjusted EPS for 2025 was $3.22, a 4% increase, driven by cost-cutting measures and improved operational efficiency [1] - The management reaffirmed its 2026 guidance, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS projected at $2.80 to $3.00 [1] Financial Performance - In Q4 2025, Pfizer's revenue reached $17.6 billion, with a 9% year-over-year increase when excluding COVID-19 products, highlighting accelerated business transformation [1] - Non-COVID products like the anticoagulant Eliquis generated $8 billion in revenue (up 8%), and the pneumonia vaccine Prevnar contributed $6.5 billion, providing stable growth to offset declines in COVID-related sales [3] Market Analysis - According to a report by CMB International, Pfizer's Q4 performance exceeded expectations, with promising data from the weight-loss pipeline PF'3944 showing a 12.3% weight reduction in the mid-dose group, indicating competitive potential against Eli Lilly's tirzepatide [2] - Analyst ratings for Pfizer range from $26 to $30, with Scotiabank maintaining a "Buy" rating and a target price of $30, emphasizing improvements in cash flow and pipeline catalysts [2] Stock Performance - Over the past week (February 5 to 11, 2026), Pfizer's stock price fluctuated by 3.55%, with a range of $26.46 to $27.94, closing at $27.73 on February 11, reflecting a daily increase of 0.43% and a trading volume of $1.157 billion [4] - Year-to-date, Pfizer's stock has risen by 13.23%, outperforming the pharmaceutical sector, which saw a slight decline of 0.02% during the same period [4]

Core Insights - Pfizer's COVID product sales have significantly declined from their peak, with projections of around $11 billion in 2024 and $6.7 billion in 2025, down from $56.7 billion in 2022. The company also faces challenges from U.S. Medicare Part D and upcoming patent expirations for key products between 2026 and 2030 [1][12] Non-COVID Revenue Growth - Non-COVID revenues for Pfizer are improving, driven by key products like Vyndaqel, Padcev, and Eliquis, as well as new launches and acquisitions. In 2023, Pfizer achieved a record number of FDA approvals, with nine new medicines and vaccines contributing to revenue growth [2][3] - Revenues from non-COVID products rose 6% operationally in 2025, with recently launched and acquired products generating $10.2 billion, reflecting a 14% operational growth year over year. Continued double-digit growth is expected for these products in 2026 [3] Strategic Acquisitions and Pipeline Development - Pfizer is focusing on rebuilding its pipeline through strategic acquisitions, investing approximately $9 billion in M&A deals in 2025, including the acquisition of Metsera and a licensing deal with 3SBio. The company plans to initiate 20 pivotal studies in 2026, targeting obesity and oncology [4][5] Competitive Landscape in Oncology - Pfizer is a major player in the oncology market, competing with companies like AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers. Each of these companies has seen significant growth in their oncology segments, with AstraZeneca's oncology sales rising 14% in 2025, Merck's Keytruda generating $31.7 billion in sales, and J&J's oncology sales increasing by 20.9% [6][8][9][10] Financial Performance and Valuation - Pfizer's stock has increased by 8.4% over the past year, compared to a 17.3% increase in the industry. The company's shares are trading at a forward price/earnings ratio of 9.33, which is lower than the industry average of 18.65 and its own 5-year mean of 10.23 [13][15] - The Zacks Consensus Estimate for Pfizer's 2026 earnings has slightly decreased from $2.99 to $2.98 per share, while the estimate for 2027 remains stable at $2.83 per share [17]

Core Insights - Pfizer's fourth-quarter results exceeded earnings and sales estimates, but total revenues declined by 3% operationally due to a 40% drop in COVID-19 product revenues [2][10] - The company reaffirmed its 2026 outlook, which anticipates lower revenues and earnings per share due to the decline in COVID product sales and upcoming patent expirations [12][13] Financial Performance - Pfizer reported a 5% year-over-year increase in earnings, despite a significant decline in revenues from COVID-19 products [2] - Total revenues for 2026 are projected to be between $59.5 billion and $62.5 billion, down from $62.6 billion in 2025 [12] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80 to $3.00, a decrease from $3.22 in 2025 [13] Product Portfolio and Pipeline - Pfizer's oncology segment, which accounts for approximately 27% of total revenues, saw an 8% revenue growth in 2025, driven by key drugs [7] - The company is expanding its obesity portfolio with the acquisition of Metsera, which added a new investigational drug, PF'3944, showing promising results in a phase IIb study [3][9] - Revenues from non-COVID products increased by 6% operationally in 2025, with recently launched and acquired products generating $10.2 billion [8] Market Challenges - Sales of COVID products, Comirnaty and Paxlovid, have significantly declined, with projections of around $5 billion in 2026, down from $6.7 billion in 2025 [15][14] - Pfizer anticipates a revenue impact of approximately $1.5 billion due to loss of exclusivity for several key products between 2026 and 2030 [16] - The redesign of Medicare Part D under the Inflation Reduction Act is expected to continue negatively affecting revenues in 2026 [17] Stock Performance and Valuation - Pfizer's stock has underperformed compared to the industry and the S&P 500, with a 5.2% increase over the past year [18] - The stock is currently trading at a price/earnings ratio of 9.20, below the industry average of 18.76 and its five-year mean of 10.24 [21] - Analysts have revised the consensus estimate for 2026 earnings down from $2.99 to $2.98 per share over the past month [24]

2026 年 2 月 5 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 公司点评 全球市场观察 公司点评 辉瑞（PFE US，买入，目标价：35.46 美元） - 减重管线数据推动估值重估 潜力 中国股指收涨，港股能源、地产与原材料领涨，信息科技、可选消费与医疗 跑输。南下资金净买入133.73亿港元，腾讯、阿里巴巴与小米净买入居前， 中芯国际、华虹半导体与钧达股份净卖出最多。A 股煤炭、建材与地产领涨， 传媒、通信与计算机跑输。马斯克团队考察光伏产业链，上市公司密集回应。 中国光伏行业协会表示太空光伏技术仍处于探索和验证的初期阶段。 美股指数下跌，信息技术、通讯服务与可选消费领跌，能源、材料与地产领 涨。美股市场软件股抛售潮继续蔓延至半导体、AI 概念股等领域，宏观数据 喜忧参半未能给市场提供支撑。资金从科技股、成长股与高估值板块向能源、 材料股、价值股与低估值板块切换。AMD 疲弱指引后暴跌 17%，拖累半导 体板块下挫，Palantir、Snowflake、Datadog 等软件与 AI 相关个股继续承压。 谷歌All in AI，第4季度云收入猛增48%，今年支出指引接近翻倍大超预期 ...

2026年2月5日 CMB国际 | 全球市场 | 股权研究 | 公司更新 辉瑞公司（PFE美国） 肥胖领域风险降低推动重估潜力 辉瑞公布了强劲的2025年第四季度业绩，收入为176亿美元（基本符合我们180亿美元 的预估），调整后净收入为38亿美元（超出我们33亿美元的预估）。尽管2025财年收入 达到626亿美元（同比下降2%），但排除COVID-19产品（Comirnaty和Paxlovid）的经 营收入同比增长6%，凸显了公司业务的强劲基础。2025财年调整后摊薄每股收益同比 增长4%至3.22美元，反映了成本削减举措的成功实施。管理层重申了2026年收入预期 为595亿美元至625亿美元，调整后每股收益为2.80美元至3.00美元。我们预计2026财年 预期将充满催化剂，包括长效GLP-1和长效胰淀素项目的关键数据公布，肥胖产品组合 和PF'4404（PD-1/VEGF）的积极临床进展，以及2L+非小细胞肺癌中SV的III期数据和 Elrexfio在复发/难治性多发性骨髓瘤中的数据。我们认为这些里程碑有望推动显著的价 值重估。 VESPER-3读数验证了每月剂量区分。 辉瑞公布了其长效GLP-1（PF ...

Market Performance - The Hang Seng Index closed at 26,847, with a slight increase of 0.05% for the day and a year-to-date increase of 4.75% [1] - The Hang Seng Technology Index decreased by 1.84% for the day and is down 2.71% year-to-date [1] - The US stock market saw the Dow Jones increase by 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51%, respectively [1] Sector Performance - In the Hong Kong market, the financial sector increased by 0.66% and is up 8.51% year-to-date, while the industrial sector decreased by 0.48% [2] - The real estate sector in Hong Kong saw a significant increase of 1.99% for the day and is up 17.13% year-to-date [2] Capital Flows - Southbound funds recorded a net inflow of 13.373 billion HKD, with Tencent, Alibaba, and Xiaomi being the top net buyers [3] - In contrast, SMIC, Hua Hong Semiconductor, and Jun Da Co. were the most sold stocks [3] US Market Trends - The US stock market experienced a sell-off in technology stocks, particularly in software and semiconductor sectors, with AMD's weak guidance leading to a 17% drop [3] - The S&P 500 software sector has seen an average decline of 25% since reaching a historical high last October [3] Company Analysis: Pfizer (PFE US) - Pfizer reported strong Q4 2025 earnings with revenue of 17.6 billion USD, slightly below the expected 18.1 billion USD, but adjusted net income exceeded expectations at 3.8 billion USD [4] - The company anticipates 2026 revenue between 59.5 billion to 62.5 billion USD, with adjusted EPS guidance of 2.80 to 3.00 USD [4] - Key upcoming milestones include data readouts for long-acting GLP-1 and Amylin projects, which are expected to drive significant valuation re-evaluation [4] Clinical Developments - Pfizer's VESPER-3 study showed a 12.3% weight loss effect at the 28-week mark for its long-acting GLP-1 candidate, with a potential 15.8% weight loss projected for a higher dose [5] - The company plans to initiate a Phase 3 study for the higher dose later this year, with detailed data expected at the ADA conference in June [5] Oncology Pipeline - Pfizer is advancing its PD-1/VEGF and ADC combination therapies, with ongoing Phase 3 trials for PF'4404 in colorectal cancer and additional trials planned for 2026 [6] - The market narrative is shifting towards pipeline execution strength, with obesity products and PF'4404 clinical progress expected to drive stock price increases [6]

Core Insights - Pfizer demonstrated robust operational resilience during its strategic transformation phase, with total revenue reaching $62.6 billion in 2025, reflecting a 6% growth in core business excluding COVID-related products [1][4] - The company maintained its 2026 performance guidance while revealing an active product pipeline, expecting to initiate approximately 20 key clinical trials in 2026, laying the foundation for long-term growth [1][4] Financial Performance - Total revenue for Q4 2025 was $17.6 billion, a 1% decrease from Q4 2024, while full-year revenue decreased by 2% to $62.6 billion [2] - Adjusted diluted EPS for Q4 was $0.66, a 5% increase year-over-year, and for the full year, it reached $3.22, up 4% [2][3] - The adjusted sales cost ratio improved to 24.2%, down from 25.8% in 2024, indicating enhanced cost management [8] Business Segments - Non-COVID product lines showed strong structural growth, with cardiovascular and vaccine segments leading the way; Eliquis generated $8 billion in revenue, a growth of 8% [4][5] - The oncology business achieved $16.8 billion in revenue, an 8% increase, with key products like Ibrance and Xtandi maintaining strong market positions despite competition [6] - COVID-related product revenues significantly declined, with Comirnaty and Paxlovid generating $4.4 billion and $2.4 billion respectively, down 18% and 59% year-over-year [7] Strategic Initiatives - Pfizer completed the acquisition of Metsera for approximately $7 billion, marking its entry into the obesity and metabolic disease treatment market [9] - The company is advancing its obesity pipeline, with promising results from the clinical trials of its long-acting GLP-1 receptor agonist [10] - Multiple oncology products received regulatory breakthroughs, enhancing the competitive edge of Pfizer's oncology portfolio [11][12] 2026 Outlook - Pfizer projects 2026 revenue between $59.5 billion and $62.5 billion, including approximately $5 billion from COVID-related products [13] - The company plans to maintain a focus on reducing debt levels and balancing its capital structure, with no share buybacks planned for 2026 [13]

Core Insights - Pfizer reported fourth-quarter 2025 adjusted earnings per share of 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, with a year-over-year earnings increase of 5% [1] - Total revenues for the quarter were $17.6 billion, a decline of 1% year-over-year on a reported basis and 3% on an operational basis, primarily due to decreased revenues from COVID-19 products [2] Revenue Breakdown - International revenues decreased by 4% on an operational basis to $8.44 billion, while U.S. revenues fell by 1% to $9.1 billion [2] - The Primary Care segment saw a 13% operational decline in sales to $7.94 billion, while Specialty Care recorded a 6% increase to $4.77 billion, and Oncology sales rose by 8% to $4.44 billion [3] Product Performance - Eliquis sales in Primary Care rose by 8% to $2.02 billion, although alliance revenues fell short of the Zacks Consensus Estimate of $2.14 billion [4] - Global revenues from the Prevnar family increased by 8% to $1.71 billion, surpassing the Zacks Consensus Estimate of $1.65 billion [5] - Comirnaty sales were $2.27 billion, down 35% year-over-year, but still beat the Zacks Consensus Estimate of $2.0 billion [6] - Paxlovid revenues dropped by 70% year-over-year to $218 million, missing the Zacks Consensus Estimate of $289 million [7] Full-Year Results - For the full year 2025, Pfizer's sales declined by 2% to $62.6 billion, exceeding the Zacks Consensus Estimate of $61.94 billion [14] - Adjusted earnings for 2025 were $3.22 per share, a 4% increase year-over-year, beating the Zacks Consensus Estimate of $3.13 [14] 2026 Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and an impending patent cliff [16] - COVID sales are projected to be around $5 billion in 2026, down from approximately $6.7 billion in 2025 [17] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80-$3.00, a decrease from 2025's EPS of $3.22 [17] Research and Development - Pfizer plans to initiate 20 pivotal studies in 2026, including 10 for ultra-long-acting obesity candidates from the Metsera acquisition [26] - Positive top-line data from a phase IIb study on PF-08653944 showed significant weight reduction, positioning Pfizer competitively against other weight loss therapies [20][21]